Retatrutide: The Next-Generation Weight Loss Drug That Beats Everything Before It

What is retatrutide?

Retatrutide (research code LY3437943) is an investigational once-weekly injectable medication developed by Eli Lilly. It belongs to a new category of drugs called triple agonists or GLP-3 agonists — a step beyond the GLP-1 drugs (semaglutide) and dual agonists (tirzepatide) currently on the market.

As of May 2026, retatrutide is not FDA approved and is only available through clinical trials. It is currently completing the TRIUMPH Phase 3 trial program — the largest obesity drug study Eli Lilly has ever run, with over 5,800 participants enrolled across multiple global trials.

‍

How does retatrutide work?

Retatrutide acts like three key gut hormones simultaneously:

• GLP-1 (glucagon-like peptide-1): Slows gastric emptying, reduces appetite, and stimulates insulin release. Same pathway as Ozempic and Wegovy.
• GIP (glucose-dependent insulinotropic polypeptide): Enhances insulin response and helps with fat metabolism. Same second receptor as Zepbound and Mounjaro.
• Glucagon receptor: The new addition. Boosts energy expenditure (calorie burning) and reduces liver fat. No currently approved obesity drug targets this receptor.

This triple mechanism reduces caloric intake and increases caloric expenditure — a dual attack on obesity that single or dual agonists cannot replicate. The glucagon component is also responsible for up to 50% reduction in liver fat seen in trials, making retatrutide potentially valuable for fatty liver disease (NASH).

‍

Phase 3 clinical trial results (2025–2026)

TRIUMPH-1 — Obesity, no diabetes (80 weeks)

Published May 21, 2026. 2,339 participants randomized to 4 mg, 9 mg, 12 mg, or placebo:

• Placebo: 3.9% weight loss
• 4 mg: 17.6% average weight loss (~37 lbs)
• 9 mg: 23.7% average weight loss (~54 lbs)
• 12 mg: 25–28.3% average weight loss (~70 lbs) — 45.3% of participants achieved ≥30% weight loss

At 104 weeks, participants with severe obesity on 9 mg or 12 mg achieved up to 30% total body weight loss — a threshold historically associated only with bariatric surgery.

TRIUMPH-4 — Obesity + knee osteoarthritis (68 weeks)

Published December 11, 2025. 445 participants:

• 12 mg: average 28.7% body weight loss
• WOMAC knee pain scores dropped by up to 75.8%
• More than 1 in 8 patients became completely pain-free
• Systolic blood pressure improved by −14.0 mmHg

TRANSCEND-T2D-1 — Type 2 diabetes (40 weeks)

Published March 2026. Participants lost an average of 36.6 lbs on the highest dose, with A1C reduced by 1.7–2.0 percentage points.

‍

Retatrutide vs. Ozempic vs. Zepbound

Retatrutide side effects

Side effects are broadly similar to other GLP-1 drugs, most common during dose escalation:

• Nausea: ~43%
• Diarrhea: ~33%
• Constipation: ~21–25%
• Vomiting: ~20–21%
• Dysesthesia (abnormal skin sensation): ~20.9% at 12 mg — not seen with semaglutide or tirzepatide
• Mild heart rate increase: 1–3 bpm from the glucagon component

Discontinuation rates due to side effects: 6–10%, consistent with semaglutide and tirzepatide.

⚠️ Retatrutide is not FDA approved. Do not purchase it from online pharmacies or peptide research sites — these products are unregulated and potentially dangerous.

‍

FDA approval timeline

• June 2023: Phase 2 results in the New England Journal of Medicine — 17.5% weight loss at 24 weeks
• December 2025: TRIUMPH-4 results — 28.7% weight loss
• March 2026: TRANSCEND-T2D-1 results — glycemic control + weight loss
• May 2026: TRIUMPH-1 results — up to 28.3% / 70 lbs over 80 weeks
• Late 2026 (est.): Remaining TRIUMPH trials complete; NDA filing anticipated
• 2027–2028 (est.): FDA review (~10 months); potential commercial launch

‍

Frequently asked questions

Is retatrutide FDA approved?

No. As of May 2026, retatrutide has no FDA approval and no approved prescribing pathway. The only legal way to access it is through an authorized clinical trial.

How much weight can you lose on retatrutide?

In TRIUMPH-1, participants on 12 mg lost an average of 28.3% of their body weight — approximately 70 pounds — over 80 weeks. At 104 weeks, up to 30% total body weight loss was recorded in severe obesity participants.

What's the difference between retatrutide and Ozempic?

Ozempic targets only GLP-1. Retatrutide targets GLP-1 plus GIP and glucagon — producing ~28% weight loss vs. ~17% for Ozempic, plus additional metabolic benefits.

Can I buy retatrutide online?

No — not safely or legally. Online peptide vendors are unregulated and dangerous. The FDA has issued warnings about unapproved GLP-1 drugs.

Is retatrutide a GLP-1 drug?

It targets GLP-1 but also GIP and glucagon — making it a "GLP-3 agonist" or triple agonist. It's next-generation compared to Ozempic and Zepbound.

‍

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved. Always consult a qualified healthcare provider before making decisions about weight loss treatment.

‍